2023 年第 4 期 第 18 卷

舒肝解郁胶囊联合盐酸度洛西汀治疗躯体形式障碍的临床效果研究

Clinical effect of Shuganjieyu capsules combined with duloxetine hydrochloride on somatoform disorder

作者：董翔1李少华2赵顺程1廖东升1李盛延1

英文作者：Dong Xiang1 Li Shaohua2 Zhao Shuncheng1 Liao Dongsheng1 Li Shengyan1

单位：1青海省第三人民医院精神科，西宁810007；2青海省第三人民医院心理科，西宁810007

英文单位：1Department of Psychiatry Third People′s Hospital of Qinghai Province Xining 810007 China; 2Department of Psychology Third People′s Hospital of Qinghai Province Xining 810007 China

关键词：躯体形式障碍；盐酸度洛西汀；舒肝解郁胶囊；临床疗效

英文关键词：Somatoformdisorder;Duloxetinehydrochloride;Shuganjieyucapsules;Clinicaleffect

• 摘要：

• 目的 探讨舒肝解郁胶囊联合盐酸度洛西汀治疗躯体形式障碍的效果和安全性。方法 选取青海省第三人民医院2019年4月至2022年4月收治的躯体形式障碍患者80例，根据随机数字表法分为对照组和观察组，各40例。2组患者均予盐酸度洛西汀肠溶片治疗，观察组加用舒肝解郁胶囊治疗。2组均治疗6周。比较2组治疗前后汉密尔顿焦虑量表（HAMA）评分、症状自评量表（SCL-90）躯体化部分评分、血清5-羟色胺水平、血清去甲肾上腺素水平、临床疗效及不良反应发生情况。结果 治疗3、6周，2组HAMA评分、SCL-90躯体化部分评分均低于治疗前，且观察组均低于对照组［治疗3周：（12.3±3.2）分比（16.4±2.3）分、（7.0±1.1）分比（8.6±1.4）分；治疗6周：（8.0±3.4）分比（10.7±3.5）分、（4.9±0.8）分比（6.5±0.9）分］（均P<0.05）；血清5-羟色胺、去甲肾上腺素水平均高于治疗前，且观察组均高于对照组（均P<0.05）。观察组临床疗效优于对照组（P＜0.05）。2组不良反应发生率比较差异无统计学意义（P＞0.05）。结论 舒肝解郁胶囊联合盐酸度洛西汀治疗躯体形式障碍安全有效，可有效提升血清5-羟色胺、去甲肾上腺素水平。

• Objective To investigate the effect and safety of Shuganjieyu capsules combined with duloxetine hydrochloride on somatoform disorder. Methods From April 2019 to April 2022, totally 80 patients with somatoform disorder were enrolled from Third People′s Hospital of Qinghai Province. According to the random number table method, they were divided into the control group and the observation group, with 40 cases in each group. All patients were treated with duloxetine hydrochloride enteric-coated tablets, and the observation group was treated with Shuganjieyu capsules on the basis of duloxetine hydrochloride enteric-coated tablets. Both groups were treated for 6 weeks. The Hamilton Anxiety Scale (HAMA) score, Symptom Checklist-90 (SCL-90) somatization score, serum 5-hydroxytryptamine (5-HT) level, serum norepinephrine (NE) level before and after treatment, clinical effect and adverse reactions were compared between the two groups. Results After 3 and 6 weeks of treatment, scores of HAMA and SCL-90 somatization in both groups were lower than those before treatment, and the scores in the observation group were lower than those in the control group ［3 weeks of treatment:(12.3±3.2) vs (16.4±2.3),(7.0±1.1) vs (8.6±1.4); 6 weeks of treatment:(8.0±3.4) vs (10.7±3.5),(4.9±0.8) vs (6.5±0.9)］(all P<0.05); serum levels of 5-HT and NE in both groups were higher than those before treatment, and the levels in the observation group were higher than those in the control group (all P<0.05). The clinical effect in the observation group was better than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Shuganjieyu capsules combined with duloxetine hydrochloride is safe and effective in the treatment of somatoform disorder, and can effectively improve serum levels of 5-HT and NE.